Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies. | The efficacy and safety of anti-CD19 CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies A meta-analysis